The validation of new CHD1L inhibitors as a therapeutic strategy for cancer
2023 · Biomedicine & Pharmacotherapy · 8 citations
https://doi.org/10.1016/j.biopha.2023.116037
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
3
Papers
13
Citations
2
h-index
0
i10-index
Sophia Clune is an academic researcher from University of Montana. The author has contributed to research in topics: PARP inhibition in cancer therapy & Protein Degradation and Inhibitors & Genomics and Chromatin Dynamics. The author has an h-index of 2, co-authored 3 publications.
ORCID: 0009-0007-2734-972XClick to start Chat